Skip to main content

Abbott launches Navitor to Treat Aortic Stenosisin India

Global healthcare company, Abbott today announcedthat it has launchedits latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, makingthe minimally invasive device availablefor people in India withsevereaortic stenosis who are at high or extreme surgical risk.With the Navitorvalve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve.TheNavitorTAVI system is the latest addition to the company'scomprehensivestructural heart transcatheter portfolio thatoffers physicians and patients less invasive optionsto treatheart diseases.

 Dr Ravinder Singh Rao, Interventional and Structural Cardiologist, Lilavati Hospital, Mumbai and Chairman RHL Heart Centre & Head Complex Angioplasty – TAVI Program aid, “TAVI or transcatheter aortic valve implantation is a viable option for patients with severe, symptomatic aortic stenosis, especially those who have high surgical risk. After a transcatheter procedure, a vast majority of our patients are able to go home in a couple of days. What is especially good for physicians is the flexible catheter enabling excellent deliverability even in patients with complex anatomies.”



 Aortic stenosis is one of the most common and life-threatening heart valve diseases. It restricts blood flow through the aortic heart valve to the rest of the body, which can lead to heart failure and, in certain cases, sudden cardiac death.[i]While many people don’t have noticeable symptoms, in India, one in 40 people aged 75 and older have severe, symptomatic aortic stenosis.[ii]For these people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty or having multiple other diseases or conditions.[iii] TAVI serves as a less invasive alternative to surgical aortic valve replacement and can reduce symptoms and improve the lives of patients with this debilitating condition.

 Prior to TAVI, the standard of care for severe aortic stenosis was surgical aortic valve replacement, but not all patients were candidates for open-heart surgery.

 More About Navitor

 Navitor features a unique fabric cuff (NaviSeal™)thatworks with the cardiac cycle to reduce or eliminate a backflow of blood around the valve frame known as paravalvular leak (PVL), a common complication following TAVI procedures. The new device is the only self-expanding TAVI system with intra-annular (within the native valve) leafletsand large frame cells–features designed to help improve access to critical coronary arteries to facilitate future interventions to treat coronary artery disease (CAD). The new design additionallyprovidesimproved hemodynamics, or better blood flow.

 The Navitordevice is implanted with Abbott's FlexNavdelivery system, whichoffers a slim design with the lowest TAVI delivery system profile, allowingtreatment of peoplewith vessels as small as 5.0 mm. The slim catheter can accommodate different aorticanatomies for stable, predictable and accurate valve delivery and placement.


 

Comments

Post a Comment

Popular posts from this blog

Country Delight Launches NMR-Tested Honey: The Gold Standard of Purity

  Country Delight continues strengthening its promise of delivering the best purity and quality by launching 100% Pure Farm Honey (NMR Tested) Country Delight, a trusted name in premium and natural essentials, has announced the launch of 100% Pure Farm Honey (NMR Tested). Country Delight’s Farm Honey is Nuclear Magnetic Resonance (NMR) tested by a certified lab in Germany, making it one of the most authentic and reliable kitchen ingredients available to Indian homes. It also undergoes rigorous testing on 36 quality parameters as per FSSAI standards, including physicochemical, antibiotic and microbial, to rule out the presence of added sugars. Honey is not just a natural sweetener; it is increasingly valued for its functional benefits. With Country Delight's NMR-tested honey, consumers can enjoy a product that supports wellness through its natural composition, which is rich in antioxidants and phytonutrients and offers advantages over refined sugars.  Adulteration with cheaper ...
Post a Comment
Read more

Prachay Capital’s Public Issue of Secured NCDs Lists on BSE Platform

Prachay Capital Limited, an RBI-registered Non-Banking Financial Company – Investment and Credit Company (NBFC-ICC), has officially listed its Secured, Rated, Redeemable Non-Convertible Debentures (NCDs) on the BSE Limited, unlocking new investment opportunities. The company successfully closed its public issue with an impressive 106% subscription, highlighting strong investor confidence. The issue, which opened on February 28, 2025, aimed to raise Rs 50 crore (excluding the greenshoe option) and closed on March 13, 2025. This landmark listing reinforces Prachay Capital’s commitment to providing stable, high-yield investment opportunities in the fixed-income sector, even amid volatile equity market conditions. The BBB-/Stable-rated NCDs by CRISIL, offering an attractive 13% per annum return with monthly interest payouts, present a compelling option for investors seeking secure fixed-income avenues. The listing event was graced by Ketan Jantre, Head of Trading Operations, BSE; Giri...
Post a Comment
Read more

Press Release: Prachay Capital Limited (Company/ Issuer / Prachay Capital) Announces Public Issue of Secured NCDs

Prachay Capital Limited, an RBI-registered Non-Banking Financial Company – Investment and Credit Company (NBFC-ICC), has announced the public issue of its Secured, Rated, Redeemable Non-Convertible Debentures (NCDs) to raise up to ₹100 Crore. The BBB-/Stable CRISIL-rated NCDs offer investors a 13% p.a. return with monthly interest payments, making it a fixed-income investment opportunity. The proceeds from this issue of NCDs will be primarily used for the stated fund utilization. Speaking about the issue, Mr Girish Murlidhar Lakhotiya, Managing Director, Prachay Capital Limited said: "This NCD issue is a key step in Prachay Capital’s expansion strategy. With our focus on structured corporate lending and investment in private debt instruments, we aim to generate strong and sustainable returns for our investors while maintaining a robust financial profile. Prachay Capital has zero delays in servicing liabilities and has Gross NPA of 0% on its Assets Under Management (AUM). The Compa...
Post a Comment
Read more